Activin-ActRII antagonists and uses for treating bone and other disorders

US10195249B2 · kind B2 · utility

Assignees

• CELGENE CORPORATION · US
• Washington University · US

Inventors

• Victoria Sung · San Francisco, US
• Randall Stevens · Plainfield, US
• William L. Smith · Mahwah, US
• Victor Schorr Sloan · Flemington, US
• Keith Hruska · Chesterfield, US
• Yifu Fang · Chesterfield, US

Key dates

• Filing date: Nov 1, 2013
• Grant date: Feb 5, 2019
• Expiry date: Nov 1, 2033

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided herein are methods for the treatment of bone disorders that are associated with kidney disease wherein the methods comprise administration of Activin-ActRIIA inhibitors to a subject in need of the treatment. Also provided herein are methods and compositions for the treatment of low turnover bone disorders wherein the methods comprise administration of Activin-ActRIIA inhibitors to a subject in need of the treatment. Further provided herein are compositions for the treatment of bone disorders that are associated with kidney disease and compositions for the treatment of low turnover bone disorders and vascular calcification.